

Listing of Claims:

Claim 1 (currently amended): A pharmaceutical composition for treatment of malignancies which comprises in combination a bisphosphonate and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use^[,] **wherein the bisphosphonate is 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.**

Claims 2-4 (canceled)

Claim 5 (currently amended): A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an HMG-CoA reductase inhibitor^[,] **wherein the bisphosphonate is 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.**

Claim 6 (currently amended): A **The** composition according to claim 1, for the inhibition of cancer cell growth or induction cancer cell apoptosis.

Claims 7-13 (canceled)

Claim 14 (previously presented): The method according to claim 5 for the inhibition of cancer cell growth or induction cancer cell apoptosis.

Claims 15-16 (canceled)

Claim 17 (new) The pharmaceutical composition according to claim 1 wherein the HMG-CoA reductase inhibitor is fluvastatin.

Claim 18 (new) The method according to claim 5 wherein the HMG-CoA reductase inhibitor is fluvastatin.